AbbVie Inc. $ABBV Shares Sold by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 335,231 shares of the company’s stock after selling 11,077 shares during the quarter. AbbVie makes up approximately 1.1% of Tocqueville Asset Management L.P.’s holdings, making the stock its 14th largest holding. Tocqueville Asset Management L.P.’s holdings in AbbVie were worth $77,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. Advisory Research Inc. grew its holdings in AbbVie by 16.4% in the third quarter. Advisory Research Inc. now owns 70,001 shares of the company’s stock valued at $16,208,000 after purchasing an additional 9,880 shares during the period. Acorns Advisers LLC raised its stake in AbbVie by 13.1% during the third quarter. Acorns Advisers LLC now owns 1,314 shares of the company’s stock worth $304,000 after purchasing an additional 152 shares during the period. Invesco Ltd. raised its stake in AbbVie by 6.3% during the third quarter. Invesco Ltd. now owns 7,438,822 shares of the company’s stock worth $1,722,385,000 after purchasing an additional 442,207 shares during the period. Seven Mile Advisory boosted its holdings in shares of AbbVie by 72.0% in the 3rd quarter. Seven Mile Advisory now owns 5,645 shares of the company’s stock valued at $1,307,000 after purchasing an additional 2,363 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of AbbVie by 22.9% in the 3rd quarter. Sei Investments Co. now owns 846,208 shares of the company’s stock valued at $195,932,000 after purchasing an additional 157,456 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of a number of research analyst reports. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.25% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple analyst takes and upgrades support upside expectations — AbbVie has a consensus “Moderate Buy” and RBC Capital started coverage with an Outperform rating and $260 price target, signaling analyst confidence in growth prospects. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Early-stage clinical progress: AbbVie reported encouraging Phase 1 results for ABBV-295 and is advancing a risankizumab dosing study — both reinforce ongoing R&D momentum in immunology and targeted therapeutics. These readouts support longer-term growth optionality. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: Allergan Aesthetics (part of AbbVie’s portfolio) continues brand strength: a top New York provider was again named #1 by Allergan Aesthetics, a small near-term signal that the aesthetics business remains competitive. New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Mixed analyst valuation view: some models lift upside tied to immunology growth while others highlight competition risk; fair-value estimates have moved only slightly, implying limited near-term re-rating. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Broader market and sector narratives (biotech growth resilience, psychiatric market expansion) provide context but are unlikely to move the stock materially absent company-specific catalysts. Josh Brown: Biotech growth stocks immune to disruption risk
• Negative Sentiment: Competitive pressure: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis, which raises near-term sales risk and may damp investor confidence in market share for a key immunology product. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Executive pay spike: reports that AbbVie’s CEO compensation rose above $30M may attract shareholder scrutiny on governance and costs. J&J, AbbVie CEOs See Pay Spike to More Than $30M

AbbVie Stock Performance

Shares of ABBV stock traded down $2.69 during mid-day trading on Friday, reaching $222.68. 750,568 shares of the company were exchanged, compared to its average volume of 7,076,792. The business’s 50 day simple moving average is $224.52 and its 200 day simple moving average is $224.48. The company has a market capitalization of $393.73 billion, a P/E ratio of 94.21, a P/E/G ratio of 0.79 and a beta of 0.34. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.